Novartis Divests Non-Core OTCs, Realigns Consumer Supply Chain

01 May 2013

• By Dan Schiff

Novartis sells six OTC brands, including Bufferin, to focus resources on core consumer health products. The firm also is realigning its consumer health supply chain, including restructuring its Lincoln, Nebraska, manufacturing plant, where the workforce will be cut 40%.

Novartis Consumer Health Inc. sold six OTC brands and is realigning its supply chain in an attempt to get back on track after taking a manufacturing plant offline.

Startup Ducere Pharma LLC bought the U.S. rights for Bufferin buffered aspirin, Comtrex (acetaminophen/dextromethorphan/phenylephrine) cough and cold remedies, Cruex (miconazole)...